

NFLIS

NATIONAL FORENSIC LABORATORY
INFORMATION SYSTEM

2013 ANNUAL REPORT



U.S. DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
OFFICE OF DIVERSION CONTROL

Contents

Highlights.....	3
Introduction.....	4
Section 1	
National and Regional Estimates.....	6
1.1 Drug Reports.....	6
1.2 Drug Cases Analyzed.....	8
1.3 National and Regional Drug Trends.....	9
Section 2	
Major Drug Categories.....	14
2.1 Narcotic Analgesics.....	14
2.2 Tranquilizers and Depressants.....	15
2.3 Anabolic Steroids.....	16
2.4 Phenethylamines.....	17
2.5 Synthetic Cannabinoids.....	18
Section 3	
GIS Analyses: XLR11 and Methylone, by Location, 2012 and 2013.....	19
Section 4	
Drugs Identified by Laboratories in Selected U.S. Cities.....	22
Appendix A: Statistical Methodology.....	24
Appendix B: Participating and Reporting Forensic Laboratories.....	28
Appendix C: NFLIS Benefits and Limitations.....	29
Appendix D: NFLIS Website and Data Query System (DQS).....	30
Public Domain Notice and Obtaining Copies of This Publication.....	31

Highlights

- An estimated total of 1,540,647 drug reports were submitted to State and local forensic laboratories in the United States from January 1 through December 31, 2013, and analyzed by March 31, 2014.
- Cannabis/THC was the most frequently identified drug (469,581 reports) in 2013, followed by cocaine (240,810 reports), methamphetamine (206,784 reports), and heroin (151,690 reports).
- Nationally, oxycodone, hydrocodone, alprazolam, clonazepam, and buprenorphine reports showed significant ($p < .05$) S-shaped trends.* Oxycodone, hydrocodone, and alprazolam showed dramatic increases from 2002 to 2010, followed by decreases in more recent years. Clonazepam showed the most dramatic increases between 2008 and 2010, followed by decreasing estimates since 2012. The most dramatic increases for buprenorphine occurred from 2005 to 2010, and estimates remained steady between 2012 and 2013. Amphetamine reports decreased slightly from 2001 to 2004, then increased through 2013.
- Reports of oxycodone, hydrocodone, and alprazolam decreased significantly between 2012 and 2013.
- Regionally, for oxycodone, all regions showed S-shaped trends similar to the national trend. Similarly, for hydrocodone, all regions but the Northeast region showed S-shaped trends similar to the national trend. The Northeast region showed a trend shaped like an upside-down U. For alprazolam, the West and Midwest regions showed linear increasing trends, while the South and Northeast regions showed S-shaped trends, with lines beginning a downward curve in 2010 and 2011, respectively. For clonazepam, the West, Midwest, and Northeast regions showed linear increasing trends, while the South region showed an S-shaped trend, with a recent leveling off and downturn beginning in 2010. For amphetamine, the Midwest, Northeast, and South regions showed upward-curving trends since 2007. For buprenorphine, the Northeast and South regions showed S-shaped trends, while the Midwest and West regions had upward-curving trends. In the Northeast and South regions, the trends began to decrease in 2011 and 2012, respectively, while the trends in the other regions continued to increase.
- In 2013, oxycodone and hydrocodone accounted for 67% of narcotic analgesic reports. Alprazolam accounted for 50% of identified tranquilizers and depressants. Among identified synthetic cannabinoids, XLR11 accounted for 55% of reports.
- Nationwide, cannabis/THC reports showed an S-shaped trend in that they decreased from 2001 through 2004, slightly increased from 2004 to 2009, and decreased from 2009 to 2013. Cocaine reports decreased between 2006 and 2013. Methamphetamine and MDMA also showed clear S-shaped trends. Methamphetamine reports increased from 2001 through 2004, decreased from 2005 through 2010, and increased since 2010. MDMA reports showed a similar but opposite trend as reports decreased from 2001 through 2003, increased slightly from 2003 through 2009, and decreased since 2009. Heroin reports showed a U-shaped trend in that they decreased from 2001 through 2005, but increased from 2006 through 2013.

* Curved trends are sometimes described as U-shaped (i.e., decreasing in earlier years and increasing in recent years) and S-shaped (i.e., two turns in the trend, roughly either increasing-decreasing-increasing or decreasing-increasing-decreasing). See Appendix A for a more detailed methodology discussion.

INTRODUCTION

The National Forensic Laboratory Information System (NFLIS) is a program of the Drug Enforcement Administration (DEA), Office of Diversion Control, that systematically collects drug identification results and associated information from drug cases submitted to and analyzed by Federal, State, and local forensic laboratories. These laboratories analyze controlled and noncontrolled substances secured in law enforcement operations across the country. NFLIS represents an important resource in monitoring illicit drug abuse and trafficking, including the diversion of legally manufactured pharmaceuticals into illegal markets. NFLIS data are used to support drug scheduling decisions and to inform drug policy and drug enforcement initiatives both nationally and in local communities around the country.

NFLIS is a comprehensive information system that includes data from forensic laboratories that handle over 91% of the Nation's nearly 1 million annual State and local drug analysis cases. Currently, NFLIS includes 50 State systems and 96 local or municipal laboratories/laboratory systems, representing a total of 272 individual laboratories. NFLIS also includes Federal data from DEA and U.S. Customs and Border Protection (CBP) laboratories.

The 2013 Annual Report presents the results of drug cases submitted to State and local laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014. Section 1 presents national and regional estimates for the 25 most frequently reported drugs, as well as national and regional trends from 2001 through 2013. Section 2 presents estimates of specific drugs by drug category. All estimates are based on the NEAR approach (National Estimates Based on All Reports). See Appendix A for details on the NEAR approach and Appendix B for a list of NFLIS participating and reporting laboratories. Data from Federal laboratories are also included in this publication. All data presented in this publication include the first, second, and third drugs that were mentioned in laboratories' reported drug items.

Sections 3 and 4 present actual reported data rather than national and regional estimates; all data reported by NFLIS State and local laboratories are included. Section 3 presents a Geographic Information System (GIS) analysis on XLR11 and methylene reports by State and by county for selected States.



Section 4 presents drugs reported by selected laboratories in cities across the country. The benefits and limitations of NFLIS are presented in Appendix C. A key area of improvement to NFLIS includes ongoing enhancements to the NFLIS Data Query System (DQS); Appendix D summarizes the DQS and NFLIS website.

NATIONAL AND REGIONAL ESTIMATES

This section describes national and regional estimates for drug reports and drug cases submitted to State and local laboratories from January through December 2013 that were analyzed by March 31, 2014. Trends are presented for selected drugs from 2001 through 2013.

National and regional drug estimates presented in the following section include all drug reports (up to three per laboratory drug item). The NEAR approach was used to produce estimates for the Nation and for the U.S. census regions. The NEAR approach uses all NFLIS reporting laboratories. Appendix A provides a detailed description of the methods used in preparing these estimates.

1.1 DRUG REPORTS

In 2013, a total of 1,540,647 drug reports were identified by State and local forensic laboratories in the United States. This estimate is a decrease of 5% from the 1,622,435 drug reports identified during 2012. Table 1.1 presents the 25 most frequently identified drugs for the Nation and for each of the U.S. census regions.

The top 25 drugs accounted for 85% of all drugs analyzed in 2013. The majority of all drugs reported in NFLIS were identified as the top four drugs, with cannabis/THC, cocaine, methamphetamine, and heroin representing 69% of all drug reports. Nationally, 469,581 drug reports were identified as cannabis/THC (30%), 240,810 as cocaine (16%), 206,784 as methamphetamine (13%), and 151,690 as heroin (10%).

In addition, seven narcotic analgesics were in the top 25 drugs: oxycodone (45,528 reports), hydrocodone (37,067 reports), buprenorphine (11,992 reports), morphine (7,955 reports), methadone (6,542 reports), hydromorphone (5,044 reports), and codeine (3,383 reports). Also included were five tranquilizers and depressants: alprazolam (36,865 reports), clonazepam (11,299 reports), diazepam (5,671 reports), phencyclidine (PCP) (5,126 reports), and carisoprodol (4,139 reports). There were also three phenethylamines: methylone (12,067 reports), amphetamine (10,612 reports), and MDMA (4,798 reports). XLR11 (19,243 reports), a synthetic cannabinoid, was also included in the top 25 drugs. Other controlled drugs included psilocin/psilocibin (4,124 reports), BZP (3,129 reports), and methylphenidate (2,618 reports). Pseudoephedrine (4,370 reports), a listed chemical, was also included in the 25 most frequently identified drugs.

Table 1.1**NATIONAL AND REGIONAL ESTIMATES FOR THE 25 MOST FREQUENTLY IDENTIFIED DRUGS¹**

Estimated number and percentage of total drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, and analyzed by March 31, 2014

Drug	National		West		Midwest		Northeast		South	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Cannabis/THC	469,581	30.48%	53,857	21.29%	154,017	39.65%	83,710	33.05%	177,997	27.55%
Cocaine	240,810	15.63%	21,173	8.37%	45,122	11.62%	55,223	21.80%	119,292	18.47%
Methamphetamine	206,784	13.42%	95,623	37.81%	35,697	9.19%	2,108	0.83%	73,356	11.36%
Heroin	151,690	9.85%	23,537	9.31%	47,824	12.31%	46,311	18.28%	34,018	5.27%
Oxycodone	45,528	2.96%	4,476	1.77%	8,357	2.15%	9,974	3.94%	22,721	3.52%
Hydrocodone	37,067	2.41%	4,732	1.87%	8,435	2.17%	2,076	0.82%	21,824	3.38%
Alprazolam	36,865	2.39%	2,663	1.05%	7,172	1.85%	5,991	2.37%	21,040	3.26%
XLR11	19,243	1.25%	2,232	0.88%	5,447	1.40%	1,965	0.78%	9,599	1.49%
Methylone	12,067	0.78%	822	0.33%	980	0.25%	2,267	0.89%	7,998	1.24%
Buprenorphine	11,992	0.78%	1,068	0.42%	2,274	0.59%	3,728	1.47%	4,921	0.76%
Clonazepam	11,299	0.73%	1,113	0.44%	2,540	0.65%	2,287	0.90%	5,359	0.83%
Amphetamine	10,612	0.69%	1,010	0.40%	2,969	0.76%	1,326	0.52%	5,308	0.82%
Morphine	7,955	0.52%	1,283	0.51%	1,953	0.50%	614	0.24%	4,106	0.64%
Methadone	6,542	0.42%	986	0.39%	1,283	0.33%	1,328	0.52%	2,945	0.46%
Noncontrolled, non-narcotic ²	6,023	0.39%	1,997	0.79%	3	0.00%	813	0.32%	3,210	0.50%
Diazepam	5,671	0.37%	830	0.33%	1,413	0.36%	526	0.21%	2,902	0.45%
Phencyclidine (PCP)	5,126	0.33%	438	0.17%	964	0.25%	2,215	0.87%	1,509	0.23%
Hydromorphone	5,044	0.33%	306	0.12%	568	0.15%	152	0.06%	4,018	0.62%
MDMA	4,798	0.31%	1,565	0.62%	1,537	0.40%	470	0.19%	1,227	0.19%
Pseudoephedrine ³	4,370	0.28%	51	0.02%	1,978	0.51%	411	0.16%	1,930	0.30%
Carisoprodol	4,139	0.27%	749	0.30%	458	0.12%	187	0.07%	2,744	0.42%
Psilocin/psilocibin	4,124	0.27%	1,129	0.45%	1,284	0.33%	391	0.15%	1,319	0.20%
Codeine	3,383	0.22%	570	0.23%	784	0.20%	557	0.22%	1,472	0.23%
1-Benzylpiperazine (BZP)	3,129	0.20%	106	0.04%	1,717	0.44%	343	0.14%	962	0.15%
Methylphenidate	2,618	0.17%	282	0.11%	888	0.23%	413	0.16%	1,034	0.16%
<i>Top 25 Total</i>	1,316,461	85.45%	222,599	88.01%	335,663	86.41%	225,388	88.98%	532,812	82.48%
<i>All Other Drug Reports</i>	224,185	14.55%	30,322	11.99%	52,788	13.59%	27,914	11.02%	113,161	17.52%
<i>Total Drug Reports⁴</i>	1,540,647	100.00%	252,921	100.00%	388,451	100.00%	253,302	100.00%	645,973	100.00%

XLR11=[1-(5-Fluoropentyl)-1H-indol-3-yl],(2,2,3,3-tetramethylcyclopropyl)methanone

MDMA=3,4-Methylenedioxyamphetamine

¹ Sample n's and 95% confidence intervals for all estimates are available on request.

² As reported by NFLIS laboratories, with no specific drug name provided.

³ Includes drug reports from a small number of laboratories that do not specify between pseudoephedrine and ephedrine.

⁴ Numbers and percentages may not sum to totals because of rounding.

1.2 DRUG CASES ANALYZED

Drug analysis results are also reported to NFLIS at the case level. These case-level data typically describe all drugs identified within a drug-related incident, although a small proportion of laboratories may assign a single case number to all drug submissions related to an entire investigation. Table 1.2 presents national estimates of the top 25 drug-specific cases. This table illustrates the number of cases that contained one or more reports of the specified drug. In 2013, there were 1,167,226 drug-specific cases submitted to and analyzed by State and local forensic laboratories, representing a 2% decrease from the 1,189,089 in 2012.

Among cases, cannabis/THC was the most common drug reported during 2013. Nationally, an estimated 37% of drug cases contained one or more reports of cannabis/THC, followed by cocaine, which was identified in 21% of all drug cases. About 17% of drug cases contained methamphetamine, 13% contained heroin, and 4% contained oxycodone. Hydrocodone and alprazolam were each reported in about 3% of cases.



Table 1.2

NATIONAL CASE ESTIMATES

Top 25 estimated number of drug-specific cases and their percentage of distinct cases, January 1, 2013, through December 31, 2013

Drug	Number	Percent
Cannabis/THC	338,662	36.97%
Cocaine	190,027	20.75%
Methamphetamine	155,794	17.01%
Heroin	116,304	12.70%
Oxycodone	36,131	3.94%
Hydrocodone	31,443	3.43%
Alprazolam	30,609	3.34%
XLR11	11,681	1.28%
Buprenorphine	10,636	1.16%
Clonazepam	10,018	1.09%
Methylone	9,364	1.02%
Amphetamine	8,952	0.98%
Morphine	6,876	0.75%
Methadone	5,781	0.63%
Diazepam	5,085	0.56%
Phencyclidine (PCP)	4,603	0.50%
Hydromorphone	4,395	0.48%
Noncontrolled, non-narcotic ¹	4,226	0.46%
Carisoprodol	3,723	0.41%
Psilocin/psilocibin	3,491	0.38%
MDMA	3,325	0.36%
Pseudoephedrine ²	2,965	0.32%
Codeine	2,926	0.32%
Tramadol	2,274	0.25%
Methylphenidate	2,174	0.24%
Top 25 Total	1,001,464	109.33%
All Other Drugs	165,762	18.10%
Total All Drugs	1,167,226³	127.43%⁴

XLR11=[1-(5-Fluoropentyl)-1H-indol-3-yl],(2,2,3,3-tetramethylcyclopropyl)methanone

MDMA=3,4-Methylenedioxymethamphetamine

¹ As reported by NFLIS laboratories, with no specific drug name provided.

² Includes drug reports from a small number of laboratories that do not specify between pseudoephedrine and ephedrine.

³ Numbers and percentages may not sum to totals because of rounding.

⁴ Multiple drugs can be reported within a single case, so the cumulative percentage exceeds 100%. The estimated national total of distinct case percentages is based on 916,000 distinct cases submitted to State and local laboratories from January 1, 2013, through December 31, 2013, and analyzed by March 31, 2014.

Drugs Reported by Federal Laboratories

The majority of drug reports presented in this section are from the DEA's System To Retrieve Information from Drug Evidence II (STRIDE). STRIDE reflects results of drug evidence from drug seizures, undercover drug buys, and other evidence analyzed at DEA laboratories across the country. STRIDE includes results for drug cases submitted by DEA agents, other Federal law enforcement agencies, and select local police agencies. Although STRIDE captures both domestic and international drug cases, the results presented in this section describe only those drug evidences obtained within the United States. In addition to drug reports from STRIDE, reports from seven U.S. Customs and Border Protection (CBP) laboratories are included.

A total of 51,841 drug reports were submitted to DEA and CBP laboratories in 2013 and analyzed by March 31, 2014, which was about 4% of the estimated 1.48 million drugs reported by NFLIS State and local laboratories during this period. In 2013, more than half of the drugs reported by DEA and CBP laboratories were identified as methamphetamine (17%), cocaine (16%), cannabis/THC (13%), or heroin (9%). Oxycodone was identified in 2% of drug reports.

MOST FREQUENTLY REPORTED DRUGS BY FEDERAL LABORATORIES¹

Number and percentage of drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, and analyzed by March 31, 2014

Drug	Number	Percent
Methamphetamine	8,622	16.63%
Cocaine	8,075	15.58%
Cannabis/THC	6,970	13.44%
Heroin	4,641	8.95%
Oxycodone	1,005	1.94%
Methylone	661	1.28%
Noncontrolled, non-narcotic ²	576	1.11%
Testosterone	367	0.71%
Phencyclidine (PCP)	308	0.59%
Hydrocodone	285	0.55%
<i>All Other Drug Reports</i>	<i>20,331</i>	<i>39.22%</i>
Total Drug Reports	51,841	100.00%

¹ Federal drug reports in this table include 49,215 reports from DEA laboratories and 2,626 reports from CBP laboratories.

² As reported by Federal laboratories, with no specific drug name provided.

1.3 NATIONAL AND REGIONAL DRUG TRENDS


The remainder of this section presents annual national and regional trends of selected drugs submitted to State and local laboratories during each annual data reference period and analyzed within three months of the end of each annual period. The trend analyses test the data for the presence of both linear and curved trends using statistical methods described in more detail in Appendix A. Curved trends are sometimes described as U-shaped (i.e., decreasing in earlier years and increasing in recent years) and S-shaped (i.e., two turns in the trend, roughly either increasing-decreasing-increasing or decreasing-increasing-decreasing). Estimates include all drug reports (up to three per laboratory drug item).

National prescription drug trends

Figures 1.1 and 1.2 present national trends for the estimated number of prescription drug reports that were identified as oxycodone, hydrocodone, alprazolam, clonazepam, amphetamine, and buprenorphine. Significant ($p < .05$) results include the following:


- Oxycodone, hydrocodone, and alprazolam reports showed S-shaped trends. These three drugs showed dramatic increases from 2002 to 2010, followed by recent downturns.

Figure 1.1 National trend estimates for oxycodone, hydrocodone, and alprazolam, January 2001–December 2013



- The S-shaped trend for clonazepam showed the most dramatic increase between 2008 and 2010, followed by a decrease since 2012.
- Amphetamine reports decreased slightly from 2001 to 2004, then increased through 2013.
- Buprenorphine also showed an S-shaped trend, with dramatic increases occurring from 2005 to 2010; moreover, its estimate remained steady between 2012 and 2013.

Figure 1.2 National trend estimates for clonazepam, amphetamine, and buprenorphine, January 2001–December 2013*



* A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.

Significance tests were also performed on differences from 2012 to 2013 in order to identify more recent changes. Across these two periods, reports of oxycodone (from 55,237 to 45,528 reports), hydrocodone (from 43,115 to 37,067 reports), and alprazolam (from 39,874 to 36,865 reports) decreased significantly ($p < .05$).



Other national drug trends

Figures 1.3 and 1.4 present national trends for reports of cannabis/THC, cocaine, methamphetamine, heroin, and MDMA. Significant ($p < .05$) results include the following:

- Cannabis/THC reports showed an S-shaped trend in that they decreased from 2001 through 2004, slightly increased from 2004 through 2009, and decreased from 2009 through 2013.
- Cocaine reports decreased between 2006 and 2013.
- Methamphetamine and MDMA also showed clear S-shaped trends. Methamphetamine reports increased from 2001 through 2004, decreased from 2005 through 2010, and increased since 2010. MDMA reports showed a similar but opposite trend as reports decreased from 2001 through 2003, increased slightly from 2003 through 2009, and decreased since 2009.
- Heroin reports showed a U-shaped trend in that they decreased from 2001 through 2005, but increased from 2006 through 2013.

Figure 1.3 National trend estimates for cannabis/THC and cocaine, January 2001–December 2013





Figure 1.4 National trend estimates for methamphetamine, heroin, and MDMA, January 2001–December 2013



More recently, from 2012 to 2013, reports of cannabis/THC (from 513,095 to 469,581 reports), cocaine (from 268,402 to 240,810), and MDMA (from 5,923 to 4,798 reports) decreased significantly, while reports of methamphetamine (from 180,187 to 206,784 reports) and heroin (from 131,624 to 151,690 reports) increased significantly ($p < .05$).

Regional prescription drug trends

Figures 1.5 through 1.10 show regional trends per 100,000 persons aged 15 or older for reports of oxycodone, hydrocodone, alprazolam, clonazepam, amphetamine, and buprenorphine from 2001 through 2013. These figures illustrate changes in prescription drugs reported over time, taking into account the population aged 15 or older of each U.S. census region. Significant ($p < .05$) trend results include the following:

- For oxycodone, all regions showed S-shaped trends similar to the national trend.
- For hydrocodone, the West, Midwest, and South regions showed S-shaped trends similar to the national trend. The Northeast region showed a trend shaped like an upside-down U.
- For alprazolam, the West and Midwest regions showed linear increasing trends. In the Northeast and South regions, the curves had a pronounced S-shape, with trend lines beginning a downward curve in 2011 and 2010, respectively.
- For clonazepam, the West, Midwest, and Northeast regions showed linear increasing trends. In the South region, the curve showed an S-shaped trend, with a recent leveling off and downturn beginning in 2010.
- For amphetamine, the Midwest, Northeast, and South regions showed upward-curving trends since 2007. No trend was evident in the West region.
- For buprenorphine, the Northeast and South regions showed S-shaped trends, while the Midwest and West regions had upward-curving trends. In the Northeast and South regions, the trends began to decrease in 2011 and 2012, respectively, while the other regions continued to increase.

More recently, between 2012 and 2013, oxycodone reports decreased significantly in all regions except the Midwest region ($p < .05$), while hydrocodone reports decreased significantly in all regions. Alprazolam decreased significantly in the West, Northeast, and South regions, but increased significantly in the Midwest region. Clonazepam decreased significantly in the Northeast region, but increased significantly in the Midwest region. Amphetamine decreased significantly in the West region, while it increased significantly in the Midwest region. Buprenorphine increased significantly in the Midwest region, but decreased significantly in the Northeast region.

Figure 1.5 Regional trends in oxycodone reported per 100,000 persons aged 15 or older, January 2001–December 2013




Figure 1.6 Regional trends in hydrocodone reported per 100,000 persons aged 15 or older, January 2001–December 2013





Figure 1.7 Regional trends in alprazolam reported per 100,000 persons aged 15 or older, January 2001–December 2013¹



Note: U.S. Census 2013 population data by age were not available for this publication. Population data for 2013 were imputed.

¹ A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.

Figure 1.8 Regional trends in clonazepam reported per 100,000 persons aged 15 or older, January 2001–December 2013




Figure 1.9 Regional trends in amphetamine reported per 100,000 persons aged 15 or older, January 2001–December 2013





Figure 1.10 Regional trends in buprenorphine reported per 100,000 persons aged 15 or older, January 2001–December 2013¹



Note: U.S. Census 2013 population data by age were not available for this publication. Population data for 2013 were imputed.

¹ A dashed trend line indicates that estimates did not meet the criteria for precision and reliability. See Appendix A for a more detailed methodology discussion.

Other regional drug trends

Figures 1.11 through 1.15 present regional trends per 100,000 persons aged 15 or older for cannabis/THC, cocaine, methamphetamine, heroin, and MDMA reports from 2001 through 2013. Significant ($p < .05$) trends include the following:

- For cannabis/THC reports, the Midwest and South regions showed linear decreasing trends. In the Northeast and West regions, the trends were S-shaped, showing sharp decreases since 2009.
- For cocaine, all four regions showed decreasing trends since about 2004.
- For methamphetamine and MDMA, the regional trends were all S-shaped, similar to the corresponding national trends. For methamphetamine, all regions showed increases beginning in 2010 and 2011. For MDMA, all regions showed decreases since 2009 and 2010.
- For heroin, the Northeast, Midwest, and West regions showed U-shaped trends. The lowest point occurred in about 2006 for these three regions. Although no trend was evident in the South region, the time series shows a sharp decrease in reports from 2002 through 2005 and later a sharper increase beginning in 2011.

Between 2012 and 2013, cannabis/THC decreased significantly in the Northeast and South regions ($p < .05$), while cocaine decreased significantly in all regions, except the Midwest region. Both methamphetamine and heroin increased significantly in the Northeast, Midwest, and South regions; methamphetamine also increased significantly in the West region. MDMA decreased significantly in the Northeast and West regions, but increased significantly in the Midwest region.




Figure 1.11 Regional trends in cannabis/THC reported per 100,000 persons aged 15 or older, January 2001–December 2013




Figure 1.12 Regional trends in cocaine reported per 100,000 persons aged 15 or older, January 2001–December 2013





Figure 1.13 Regional trends in methamphetamine reported per 100,000 persons aged 15 or older, January 2001–December 2013¹



Note: U.S. Census 2013 population data by age were not available for this publication. Population data for 2013 were imputed.

¹ A dashed trend line indicates that estimates did not meet the criteria for precision or reliability. See Appendix A for a more detailed methodology discussion.

Figure 1.14 Regional trends in heroin reported per 100,000 persons aged 15 or older, January 2001–December 2013





Figure 1.15 Regional trends in MDMA reported per 100,000 persons aged 15 or older, January 2001–December 2013



Heroin

MAJOR DRUG CATEGORIES

Section 2 presents national and regional estimates of specific drugs by drug category using the NEAR approach (see Appendix A for a description of the methodology). The first, second, and third drugs mentioned in laboratories' drug items are included. An estimated 1,540,647 drug reports were submitted to State and local laboratories during 2013 and were analyzed by March 31, 2014.

2.1 NARCOTIC ANALGESICS

Narcotic analgesics, or pain relievers, require a prescription and are used to treat moderate to severe pain. However, every year thousands of people die from abuse and misuse of narcotic analgesics. In 2012, 5% of people aged 12 or older reported past year nonmedical use of prescription pain relievers, including 10% of adults aged 18 to 25.¹

A total of 123,498 narcotic analgesic reports were identified by NFLIS laboratories in 2013, representing 8% of all drug reports (Table 2.1). Oxycodone (37%) and hydrocodone (30%) accounted for the majority of all narcotic analgesic reports. Other narcotic analgesics reported included buprenorphine (10%), morphine (6%), methadone (5%), hydromorphone (4%), and codeine (3%). The types of narcotic analgesics reported varied considerably by region (Figure 2.1). In comparison with reports from other regions in the country, the Northeast region reported the highest percentage of oxycodone (52%) and the highest percentage of buprenorphine (19%). Hydrocodone accounted for 34% of narcotic analgesics in the West and Midwest regions and 33% in the South region. The West region reported the highest percentage of morphine (9%).

¹ Center for Behavioral Health Statistics and Quality. (2013, September). Table 1.54B. Nonmedical use of pain relievers in lifetime, past year, and past month among persons aged 12 or older, by demographic characteristics: Percentages, 2011 and 2012. In *Results from the 2012 National Survey on Drug Use and Health: Detailed tables*. Retrieved from <http://www.samhsa.gov/data/NSDUH/2012SummNatFindDetTables/DetTabs/NSDUH-DetTabsSect1peTabs47to92-2012.htm#Tab1.54B>


Table 2.1 Notes

¹ Includes drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

² Numbers and percentages may not sum to 100% because of rounding.

Table 2.1 NARCOTIC ANALGESICS Number and percentage of narcotic analgesic reports, 2013 ¹		
Narcotic Analgesic Reports	Number	Percent
Oxycodone	45,528	36.87%
Hydrocodone	37,067	30.01%
Buprenorphine	11,992	9.71%
Morphine	7,955	6.44%
Methadone	6,542	5.30%
Hydromorphone	5,044	4.08%
Codeine	3,383	2.74%
Tramadol	2,496	2.02%
Oxymorphone	1,731	1.40%
Fentanyl	945	0.77%
Propoxyphene	208	0.17%
Mitragynine	181	0.15%
Meperidine	113	0.09%
Dextropropoxyphene	104	0.08%
Pentazocine	66	0.05%
Other narcotic analgesics	142	0.11%
Total Narcotic Analgesic Reports ²	123,498	100.00%
Total Drug Reports	1,540,647	

Figure 2.1 Distribution of narcotic analgesic reports within region, 2013¹



2.2 TRANQUILIZERS AND DEPRESSANTS

Tranquilizers and depressants are used to treat a variety of health problems, including sleep issues, anxiety, panic attacks, muscle spasms, and seizures. Tranquilizers and depressants are often used with other drugs to add to the other drugs' high or to deal with their side effects.² In 2012, there were 17,407 substance abuse treatment admissions in which tranquilizers were the primary substance of abuse, a slight decrease from the 19,174 admissions in 2011.³

Approximately 5% of all drug reports in 2013, or 73,135 reports, were identified by NFLIS laboratories as tranquilizers and depressants (Table 2.2). Alprazolam accounted for 50% of reported tranquilizers and depressants. Approximately 15% of tranquilizers and depressants were identified as clonazepam. Alprazolam was identified in more than one-half of the tranquilizers and depressants reported in the South region (56%) (Figure 2.2). Clonazepam accounted for 17% of tranquilizers and depressants identified in the Midwest and Northeast regions. The West region reported the highest percentage of diazepam (11%), while the Northeast region reported the highest percentage of PCP (17%).

² U.S. Drug Enforcement Administration. (2011). *Drugs of abuse: A DEA resource guide* (2011 ed.). Retrieved from http://www.justice.gov/dea/docs/drugs_of_abuse_2011.pdf


³ Center for Behavioral Health Statistics and Quality. (2014, July). Table 1.1a. Admissions aged 12 and older, by primary substance of abuse: 2002–2012 number. In *Treatment Episode Data Set (TEDS): 2002–2012. National admissions to substance abuse treatment services* (p. 43, HHS Publication No. SMA 14–4850, BHSIS Series S–71). Retrieved from http://www.samhsa.gov/data/2K14/TEDS2012NA/TEDS2012N_Web.pdf

Table 2.2

TRANQUILIZERS AND DEPRESSANTS
Number and percentage of tranquilizers and depressant reports, 2013¹

Tranquilizer and Depressant Reports	Number	Percent
Alprazolam	36,865	50.41%
Clonazepam	11,299	15.45%
Diazepam	5,671	7.75%
Phencyclidine (PCP)	5,126	7.01%
Carisoprodol	4,139	5.66%
Lorazepam	2,343	3.20%
Zolpidem	2,019	2.76%
Ketamine	1,383	1.89%
Cyclobenzaprine	1,298	1.77%
Hydroxyzine	372	0.51%
Temazepam	355	0.49%
Butalbital	338	0.46%
Pregabalin	285	0.39%
Prochlorperazine	275	0.38%
Phenazepam	163	0.22%
Other tranquilizers and depressants	1,204	1.65%
Total Tranquilizer and Depressant Reports²	73,135	100.00%
Total Drug Reports	1,540,647	

Figure 2.2 Distribution of tranquilizer and depressant reports within region, 2013¹



¹ Includes drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

² Numbers and percentages may not sum to 100% because of rounding.

2.3 ANABOLIC STEROIDS

Anabolic steroids are synthetic variants of the naturally occurring male hormone testosterone. Although most steroids are smuggled into the United States from abroad, they are also diverted from legitimate sources through theft or inappropriate prescribing. Steroids are ingested orally, injected intramuscularly, or applied to the skin (creams or patches). The doses abused are often 10 to 100 times higher than approved dosages for medical treatment. Although anabolic steroids are usually not associated with overdoses, they can cause serious health problems, such as cancer, stunted growth, coronary disease, liver damage, and behavioral and mental health issues.⁴

During 2013, a total of 3,658 drug reports were identified as anabolic steroids (Table 2.3). The most commonly identified anabolic steroid was testosterone (50%), followed by trenbolone (9%), nandrolone (8%), methandrostenolone (7%), and stanozolol (7%). Testosterone accounted for 54% of anabolic steroids in the Midwest region, 51% in the South region, 49% in the West region, and 44% in the Northeast region (Figure 2.3). Trenbolone accounted for 11% of anabolic steroids in the South region. The West region reported the highest percentage of nandrolone (11%), and the Midwest region reported the highest percentage of methandrostenolone (9%).

Table 2.3


ANABOLIC STEROIDS
Number and percentage of anabolic steroid reports, 2013¹

Anabolic Steroid Reports	Number	Percent
Testosterone	1,845	50.44%
Trenbolone	333	9.11%
Nandrolone	294	8.05%
Methandrostenolone	272	7.44%
Stanozolol	256	7.00%
Boldenone	171	4.68%
Oxandrolone	119	3.26%
Oxymetholone	87	2.39%
Drostanolone	70	1.91%
Mesterolone	33	0.90%
Methyltestosterone	28	0.76%
Methenolone	13	0.37%
Dehydrochloromethyltestosterone	11	0.30%
Desoxymethyltestosterone	11	0.30%
Fluoxymesterone	11	0.30%
Other anabolic steroids	102	2.79%
Total Anabolic Steroid Reports²	3,658	100.00%
Total Drug Reports	1,540,647	

⁴ See text reference footnote 2 in the left column of p. 15.



Figure 2.3 Distribution of anabolic steroid reports within region, 2013¹



¹ Includes drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

² Numbers and percentages may not sum to 100% because of rounding.

2.4 PHENETHYLAMINES

Phenethylamines are a class of designer drugs that when taken produce effects similar to stimulants and/or hallucinogens. Side effects associated with the abuse of phenethylamines include tachycardia, hypertension, hyperthermia, seizures, sweating, headache, paranoia, hallucinations, delusions, and even death. Synthetic phenethylamines (and more specifically, synthetic cathinones) are often marketed as “bath salts” and other ordinary household goods.^{5,6}

NFLIS laboratories identified 245,648 phenethylamine reports in 2013, representing 16% of all drug reports (Table 2.4). Of these, 84% were identified as methamphetamine. Among the other phenethylamine reports, 5% were identified as methylone and 4% as amphetamine. As shown in Figure 2.4, methamphetamine accounted for 96% of phenethylamine reports in the West region, 79% in the Midwest and South regions, and 27% in the Northeast region. Approximately 30% of the phenethylamines reported in the Northeast region were methylone. The Northeast region also reported the highest percentages of amphetamine (17%) and MDMA (6%).

Table 2.4

PHENETHYLAMINES

Number and percentage of phenethylamine reports, 2013¹

Phenethylamine Reports	Number	Percent
Methamphetamine	206,784	84.18%
Methylone	12,067	4.91%
Amphetamine	10,612	4.32%
MDMA	4,798	1.95%
alpha-PVP	2,240	0.91%
Lisdexamfetamine	1,839	0.75%
2C-I-NBOMe	1,286	0.52%
MDPV	1,051	0.43%
4-MEC	986	0.40%
Phentermine	595	0.24%
2C-C-NBOMe	405	0.16%
MDA	395	0.16%
Ephedrine	292	0.12%
2C-B-NBOMe	177	0.07%
Pentedrone	156	0.06%
Other phenethylamines	1,965	0.80%

Total Phenethylamine Reports² 245,648 100.00%

Total Drug Reports 1,540,647

MDMA=3,4-Methylenedioxymethamphetamine

alpha-PVP=alpha-Pyrrolidinopentiophenone

2C-I-NBOMe=2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

MDPV=3,4-Methylenedioxypropylvalerone

4-MEC=4-Methyl-N-Ethylcathinone

2C-C-NBOMe=2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

MDA=3,4-methylenedioxymethamphetamine

2C-B-NBOMe=2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine





Figure 2.4 Distribution of phenethylamine reports within region, 2013¹



MDMA=3,4-Methylenedioxymethamphetamine

¹ Includes drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

² Numbers and percentages may not sum to 100% because of rounding.

⁵ Rannazzisi, J. T. (2013, September 25). Statement of Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, before the Caucus on International Narcotics Control, United States Senate, for a hearing entitled “Dangerous Synthetic Drugs.” Retrieved from <http://www.justice.gov/dea/pr/speeches-testimony/2013t/092513t.pdf>

⁶ U.S. Drug Enforcement Administration, Office of Intelligence Warning, Plans and Programs. (2013, November). 2013 National drug threat assessment summary (DEA-NWW-DIR-017-13). Retrieved from <http://www.justice.gov/dea/resource-center/DIR-017-13%20NDTA%20Summary%20final.pdf>

2.5 SYNTHETIC CANNABINOIDS


Synthetic cannabinoids, commonly known as “synthetic marijuana,” “K2,” or “Spice,” are man-made chemicals that are applied onto plant materials and are often sold as “herbal incense” or “potpourri.” The side effects associated with the use of synthetic cannabinoids include agitation, anxiety, nausea, vomiting, tachycardia, high blood pressure, seizures, hallucinations, and suicidal thoughts.⁷ According to the 2013 Monitoring the Future survey, 4.0% of 8th graders, 7.4% of 10th graders, and 7.9% of 12th graders used synthetic cannabinoids during the past year, making synthetic cannabinoids the second most frequently used illegal drug among high school sophomores and the third most frequently used drug among high school freshmen and seniors.⁸

A total of 35,101 synthetic cannabinoid reports were identified during 2013, accounting for about 2% of all drugs reported (Table 2.5). XLR11 accounted for 55% of all synthetic cannabinoid reports in 2013. AB-FUBINACA accounted for approximately 7%, and UR-144 and 5F-PB-22 each accounted for approximately 6%. In each region, XLR11 accounted for half or more of all synthetic cannabinoid reports (Figure 2.5). In the South region, 9% of synthetic cannabinoids were reported as AB-FUBINACA. The Northeast region reported the highest percentage of UR-144 (7%), and the Midwest and West regions reported the highest percentages of 5F-PB-22 (9% each).

Table 2.5 SYNTHETIC CANNABINOIDS Number and percentage of synthetic cannabinoid reports, 2013 ¹		
Synthetic Cannabinoid Reports	Number	Percent
XLR11	19,243	54.82%
AB-FUBINACA	2,426	6.91%
UR-144	2,077	5.92%
5F-PB-22	1,952	5.56%
PB-22	1,800	5.13%
AM-2201	1,256	3.58%
AB-PINACA	965	2.75%
AKB48 N-(5-fluoropentyl)	860	2.45%
JWH-018 (AM-678)	364	1.04%
AKB48	363	1.03%
JWH-250	210	0.60%
JWH-122	185	0.53%
JWH-210	154	0.44%
MAM-2201	148	0.42%
STS-135	115	0.33%
Other synthetic cannabinoids	2,984	8.50%
Total Synthetic Cannabinoid Reports ²	35,101	100.00%
Total Drug Reports	1,540,647	

¹ Includes drug reports submitted to laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.
² Numbers and percentages may not sum to 100% because of rounding.

Figure 2.5 Distribution of synthetic cannabinoid reports within region, 2013¹



XLR11=[1-(5-Fluoro-pentyl)1H-indol-3-yl],(2,2,3,3-tetramethylcyclopropyl)methanone
AB-FUBINACA=N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
UR-144=(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
5F-PB-22=(Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate)
PB-22=(Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate)
AM-2201=(1-(5-Fluoropentyl)-3-(1-naphthoyl)indole)
AB-PINACA=N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
AKB48 N-(5-fluoropentyl)=N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
JWH-018 (AM678)=(1-Pentyl-3-(1-naphthoyl)indole)
AKB48=N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide
JWH-250=(1-Pentyl-3-(2-methoxyphenylacetyl)indole)
JWH-122=(1-Pentyl-3-(4-methyl-1-naphthoyl)indole)
JWH-210=1-pentyl-3-(4-ethyl-1-naphthoyl)indole
MAM-2201=[1-(5-fluoropentyl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)methanone
STS-135=1-(5-fluoropentyl)-N-(tricyclo[3.3.1.1.3,7]dec-1-yl)-1H-indole-3-carboxamide

⁷ Office of National Drug Control Policy, The White House. (n.d.). Synthetic drugs (a.k.a. K2, Spice, Bath Salts, etc.). Retrieved from <http://www.whitehouse.gov/ondcp/ondcp-fact-sheets/synthetic-drugs-k2-spice-bath-salts>
⁸ Johnston, L. D., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Miech, R. A. (2014, June). Table 2-2. Trends in annual prevalence of use of various drugs for 8th, 10th, and 12th graders, college students, and young adults (ages 19-28). In *Monitoring the Future national survey results on drug use, 1975-2013: Volume I, Secondary school students* (p. 53). Retrieved from http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2013.pdf

GIS ANALYSES: XLR11 AND METHYLONE, BY LOCATION, 2012 AND 2013

One of the unique features of NFLIS is the ability to analyze and monitor, by the county of origin, variation in drugs reported by laboratories. By using Geographic Information System (GIS) analyses, NFLIS can provide information on drug seizure locations.

This section presents data at the State and county levels for the percentage of drug reports identified as XLR11 and methylone at two points in time—2012 and 2013. Reports of XLR11 and methylone increased substantially in NFLIS between 2012 and 2013. Methylone was first reported in NFLIS in 2011; XLR11 was first reported in 2012. In 2012, XLR11 and methylone first appeared in the NFLIS top 25 most frequently identified drugs, and by 2013 they were the 8th and the 10th most frequently reported drugs, respectively.

The GIS data presented here are based on information provided to the forensic laboratories by the submitting law enforcement agencies (Figures 3.1 to 3.8). The information submitted by law enforcement includes the ZIP Code or county of origin associated with the drug seizure incident or the name of the submitting law enforcement agency. When a ZIP Code or county of origin is unavailable, the drug seizure or incident is assigned to the same county as the submitting law enforcement agency. If the submitting agency is unknown, the seizure or incident is assigned to the county in which the laboratory completing the analyses is located.

It is important to note that these data may not include all drug items seized at the State and county levels. Instead, these data represent only those items that were submitted and analyzed by forensic laboratories. In addition, some laboratories within several States are not currently reporting data to NFLIS, and their absence may affect the relative distribution of drugs seized and analyzed. Nevertheless, these data can serve as an important source for identifying abuse and trafficking trends and patterns across and within States.

Figure 3.1 Percentage of total drug reports identified as XLR11, by State, 2012*




Figure 3.2 Percentage of total drug reports identified as XLR11, by State, 2013*




Figure 3.3 Percentage of total drug reports identified as methylone, by State, 2012*





Figure 3.4 Percentage of total drug reports identified as methylone, by State, 2013*



* Includes drug reports submitted to State and local laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

Figure 3.5 Percentage of total drug reports identified as XLR11 in Indiana, by county, 2012*




Figure 3.6 Percentage of total drug reports identified as XLR11 in Indiana, by county, 2013*




Figure 3.7 Percentage of total drug reports identified as methylone in New Jersey, by county, 2012*





Figure 3.8 Percentage of total drug reports identified as methylone in New Jersey, by county, 2013*




* Includes drug reports submitted to State and local laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

DRUGS IDENTIFIED BY LABORATORIES IN SELECTED U.S. CITIES

NFLIS can be used to monitor drugs reported by forensic laboratories across the country, including laboratories in large U.S. cities. This section presents drug analysis results of all drug reports (up to three per laboratory drug item) submitted to State and local laboratories from January 1, 2013, through December 31, 2013, that were analyzed by March 31, 2014.

This section presents data for the four most common drugs reported by NFLIS laboratories located in selected cities. The laboratories representing selected cities are presented in the summary table on the next page. The following results highlight geographic differences in the types of drugs abused and trafficked, such as the higher levels of methamphetamine reporting on the West Coast and cocaine reporting on the East Coast.


Nationally, 15% of all drugs in NFLIS were identified as cocaine (Table 1.1). Laboratories representing cities in the South and Northeast reported the highest levels of cocaine, including McAllen (64%), Miami (48%), El Paso (41%), Orlando (38%), Columbia (32%), New York City (30%), Philadelphia (28%), Tampa (28%), Baltimore (24%), Houston (24%), and Augusta (22%). Denver (23%) and San Francisco (22%), cities located in the West, also reported a high percentage of cocaine.



The highest percentages of methamphetamine were reported by laboratories representing cities in the West and Midwest, such as Fresno (59%), Spokane (47%), Sacramento (42%), San Diego (42%), Minneapolis-St. Paul (38%), Lincoln (37%), Portland (36%), Rapid City (33%), and Los Angeles (32%). Dallas (31%), Oklahoma City (30%), and Houston (29%), cities located in the South, also reported a high percentage of drugs identified as methamphetamine. Nationally, 14% of drugs in NFLIS were identified as methamphetamine.

The highest percentages of heroin were reported by laboratories representing the Northeastern cities of Pittsburgh (36%) and Augusta (22%); the Midwestern cities of Cincinnati (28%) and Chicago (22%); and the Western cities of Portland (22%) and Seattle (21%). Nationally, 10% of all drugs in NFLIS were identified as heroin.

Among controlled prescription drugs, the highest percentages of oxycodone were reported by laboratories representing Augusta (12%), Tampa (6%), and Nashville (6%). Nationally, 3% of drugs in NFLIS were identified as oxycodone. Birmingham (8%), Nashville (8%), and Montgomery (7%) reported the highest percentages of hydrocodone, and at a higher percentage than the NFLIS national estimate of 2%. Columbia (6%) reported the highest percentage of alprazolam. Nationally, 2% of drugs in NFLIS were identified as alprazolam. Salt Lake City (6%) and Las Vegas (5%) reported the highest percentages of XLR11, while Miami (8%) and Orlando (6%) reported the highest percentages of methylone (8%). Approximately 1% of drugs in NFLIS were identified as XLR11 or methylone.



Selected Laboratories
Atlanta (Georgia State Bureau of Investigation—Decatur Laboratory)
Augusta (Maine Department of Human Services)
Baltimore (Baltimore City Police Department)
Baton Rouge (Louisiana State Police)
Birmingham (Alabama Department of Forensic Sciences—Birmingham Laboratory)
Cheyenne (Wyoming State Crime Laboratory)
Chicago (Illinois State Police—Chicago Laboratory)
Cincinnati (Hamilton County Coroner's Office)
Columbia (South Carolina Law Enforcement Division—Columbia Laboratory)
Dallas (Texas Department of Public Safety—Garland Laboratory)
Denver (Denver Police Department Crime Laboratory)
Des Moines (Iowa Division of Criminal Investigations)
El Paso (Texas Department of Public Safety—El Paso Laboratory)
Fresno (California Department of Justice—Fresno Laboratory and Fresno County Sheriff's Forensic Laboratory)
Houston (Texas Department of Public Safety—Houston Laboratory and Harris County Medical Examiner's Office)
Indianapolis (Indianapolis-Marion County Forensic Laboratory)
Jackson (Mississippi Department of Public Safety—Jackson Laboratory and Jackson Police Department Crime Laboratory)
Las Vegas (Las Vegas Metropolitan Police Crime Laboratory)
Lincoln (Nebraska State Patrol Criminalistics Laboratory—Lincoln Laboratory)
Little Rock (Arkansas State Crime Laboratory)
Los Angeles (Los Angeles Police Department and Los Angeles County Sheriff's Department)
Louisville (Kentucky State Police—Louisville Laboratory)
McAllen (Texas Department of Public Safety—McAllen Laboratory)
Miami (Miami-Dade Police Department Crime Laboratory)
Minneapolis-St. Paul (Minnesota Bureau of Criminal Apprehension—Minneapolis Laboratory)
Montgomery (Alabama Department of Forensic Sciences—Montgomery Laboratory)
Nashville (Tennessee Bureau of Investigation—Nashville Laboratory)
New York City (New York City Police Department Crime Laboratory)
Oklahoma City (Oklahoma State Bureau of Investigation—Oklahoma City Laboratory)
Orlando (Florida Department of Law Enforcement—Orlando Laboratory)
Philadelphia (Philadelphia Police Department Forensic Science Laboratory)
Phoenix (Phoenix Police Department)
Pittsburgh (Allegheny County Coroner's Office)
Portland (Oregon State Police Forensic Services Division—Portland Laboratory)
Rapid City (Rapid City Police Department)
Raleigh (North Carolina State Bureau of Investigation—Raleigh Laboratory)
Sacramento (Sacramento County District Attorney's Office)
Salt Lake City (Utah State Crime Laboratory—Salt Lake City Laboratory)
San Diego (San Diego Police Department)
San Francisco (San Francisco Police Department)
Santa Fe (New Mexico Department of Public Safety—Santa Fe Laboratory)
Seattle (Washington State Patrol—Seattle Laboratory)
Spokane (Washington State Patrol—Spokane Laboratory)
St. Louis (St. Louis Police Department)
Tampa (Florida Department of Law Enforcement—Tampa Laboratory)
Topeka (Kansas Bureau of Investigation—Topeka Laboratory)

Overview

Since 2001, NFLIS publications have included national and regional estimates for the number of drug reports and drug cases analyzed by State and local forensic laboratories in the United States. This appendix discusses the methods used for producing these estimates, including sample selection, weighting, imputation, and trend analysis procedures. RTI International, under contract to the DEA, began implementing NFLIS in 1997. Results from a 1998 survey (updated in 2002, 2004, 2007, and 2012) provided laboratory-specific information, including annual caseloads, which was used to establish a national sampling frame of all State and local forensic laboratories that routinely perform drug chemistry analyses. A probability proportional to size (PPS) sample was drawn on the basis of annual cases analyzed per laboratory, resulting in a NFLIS national sample of 29 State laboratory systems and 31 local or municipal laboratories, and a total of 168 individual laboratories (see Appendix B for a list of sampled NFLIS laboratories).

Estimates appearing in this publication are based on cases and items *submitted* to laboratories between January 1, 2013, and December 31, 2013, and *analyzed* by March 31, 2014. Analysis has shown that approximately 95% of cases submitted during an annual period are analyzed within three months of the end of the annual period (not including the approximately 30% of cases that are never analyzed).

For each drug item (or exhibit) analyzed by a laboratory in the NFLIS program, up to three drugs can be reported to NFLIS and counted in the estimation process. A drug-specific case is one for which the specific drug was identified as the first, second, or third drug report for any item associated with the case. A drug-specific report is the total number of reports of the specific drug.

Currently, laboratories representing more than 91% of the national drug caseload participate in NFLIS, with about 88% of the national caseload reported for each reporting period. This reporting provided an opportunity to implement a method, referred to as NEAR (National Estimates Based on All Reports), that has strong statistical advantages for producing national and regional estimates.

NEAR Methodology

In NFLIS publications before 2011, data reported by nonsampled laboratories were not used in national or regional estimates.⁹ However, as the number of nonsampled laboratories reporting to NFLIS increased,¹⁰ it began to make sense to consider ways to utilize the data they submitted. Under NEAR, the “volunteer” laboratories (i.e., the reporting nonsampled laboratories) represent themselves and are no longer represented by the reporting sampled laboratories. The volunteer laboratories are assigned weights of one, and hence the weights of the sampled and responding laboratories are appropriately adjusted downward. The outcome is that the estimates are more precise, especially for recent years, which include a large number of volunteer laboratories. More precision allows for more power to detect trends and fewer suppressed estimates in Tables 1.1 and 1.2 of the NFLIS annual and midyear reports.

NEAR imputations and adjusting for missing monthly data in reporting laboratories

Because of technical and other reporting issues, some laboratories do not report data for every month during a given reporting period, resulting in missing monthly data. If a laboratory reports fewer than six months of data for the annual estimates (fewer than three months for the semiannual estimates), it is considered nonreporting, and its reported data are not included in the estimates. Otherwise, imputations are performed separately by drug for laboratories that are missing monthly data, using drug-specific proportions generated from laboratories that are reporting all months of data. This imputation method is used for cases, items, and drug-specific reports and accounts for both the typical month-to-month variation and the size of the laboratory requiring imputation. The general idea is to use the nonmissing months to assess the size of the laboratory requiring imputation and then to apply the seasonal pattern exhibited by all laboratories with no missing data. Imputation of monthly case counts are created using the following ratio (r_L):

$$r_L = \frac{\sum_{m \in R_L} c_{L,m}}{\sum_{m \in R_L} c_{.,m}},$$

where

- R_L = set of all nonmissing months in laboratory L ,
- $c_{L,m}$ = case count for laboratory L in month m , and
- $c_{.,m}$ = mean case counts for all laboratories reporting complete data.

⁹ The case and item loads for the nonsampled laboratories were used in calculating the weights.

¹⁰ In 2013, for example, out of 100 nonsampled laboratories and laboratory systems, 80 (or 80%) reported.

Monthly item counts are imputed for each laboratory using an estimated item-to-case ratio (s_L) for nonmissing monthly item counts within the laboratory. The imputed value for the missing monthly number of items in each laboratory is calculated by multiplying $c_{L,m}$ by s_L .

$$s_L = \frac{\sum_{m \in R_L} i_{L,m}}{\sum_{m \in R_L} c_{L,m}},$$

where

- R_L = set of all nonmissing months in laboratory L ,
- $i_{L,m}$ = item count for laboratory L in month m , and
- $c_{L,m}$ = case count for laboratory L in month m .

Drug-specific case and report counts are imputed using the same imputation techniques presented above for the case and item counts. The total drug, item, and case counts are calculated by aggregating the laboratory and laboratory system counts for those with complete reporting and those that require imputation.

NEAR imputations and drug report-level adjustments

Most forensic laboratories classify and report case-level analyses in a consistent manner in terms of the number of vials of a particular pill. A small number, however, do not produce drug report-level counts in the same way as those submitted by the vast majority. Instead, they report as items the count of the individual pills themselves. Laboratories that consider items in this manner also consider drug report-level counts in this same manner. Drug report-to-case ratios for each drug were produced for the similarly sized laboratories, and these drug-specific ratios were then used to adjust the drug report counts for the relevant laboratories.

NEAR weighting procedures

Each NFLIS reporting laboratory was assigned a weight to be used in the calculation of design-consistent, nonresponse-adjusted estimates. Two weights were created: one for estimating cases and one for estimating drug reports. The weight used for case estimation was based on the caseload for every laboratory in the NFLIS population, and the weight used for drug reports' estimation was based on the item load for every laboratory in the NFLIS population. For reporting laboratories, the caseload and item load used in weighting were the reported totals. For nonreporting laboratories, the caseload and item load used in weighting were obtained from an updated laboratory survey administered in 2013.

When the NFLIS sample was originally drawn, two stratifying variables were used: (1) type of laboratory (State system or municipal or county laboratory) and (2) determination of

“certainty” laboratory status. To ensure that the NFLIS sample had strong regional representation, U.S. census regions were used as the geographical divisions to guide the selection of certainty laboratories and systems. Some large laboratories were automatically part of the original NFLIS sample because they were deemed critically important to the calculation of reliable estimates. These laboratories are called “certainty laboratories.” The criteria used in selecting the certainty laboratories included (1) size, (2) region, (3) geographical location, and (4) other special considerations (e.g., strategic importance of the laboratory).

Each weight has two components, the design weight and the nonresponse adjustment factor, the product of which is the final weight used in estimation. After imputation, the final item weight is based on the item count, and the final case weight is based on the case count of each laboratory or laboratory system. The final weights are used to calculate national and regional estimates. The first component, the design weight, is based on the proportion of the caseload and item load of the NFLIS universe¹¹ represented by the individual laboratory or laboratory system. This step takes advantage of the original PPS sample design and provides precise estimates as long as the drug-specific case and report counts are correlated with the overall caseload and item load.¹²

For noncertainty reporting laboratories in the sample (and reporting laboratories in the certainty strata with nonreporting laboratories), the design-based weight for each laboratory is calculated as follows:

$$\text{Design Weight}_i = A / (B \times \text{Case [item] Count for Laboratory or Laboratory System } i),$$

where

- i = i th laboratory or laboratory system;
- A = sum of the case (item) counts for all of the laboratories and laboratory systems (sampled and nonsampled) within a specific stratum, excluding certainty strata and the volunteer stratum; and
- B = number of sampled laboratories and laboratory systems within the same stratum, excluding certainty strata and the volunteer stratum.

Certainty laboratories were assigned a design weight of one.¹³

¹¹ See the Introduction of this publication for a description of the NFLIS universe.

¹² Lohr, S. L. (2010). *Sampling: Design and analysis* (2nd ed., pp. 231-234). Boston, MA: Brooks/Cole.

¹³ With respect to the design weight, reporting laboratories and laboratory systems in certainty strata with nonreporting laboratories and laboratory systems are treated the same way as reporting noncertainty sampled laboratories and laboratory systems. This is done to reduce the variance; otherwise, all reporting laboratories and laboratory systems in these strata would get the same weight regardless of their size.

The second component, the nonresponse adjustment factor, adjusts the weights of the reporting and sampled laboratories to account for the nonreporting and sampled laboratories. The nonresponse (*NR*) adjustment, for both certainty and noncertainty laboratories, is calculated as follows:

$$NR_j = C/D,$$

where

- j = stratum;
- C = number of sampled laboratories and laboratory systems in the stratum, excluding the volunteer stratum; and
- D = number of laboratories and laboratory systems in the stratum that were both sampled and reporting.

Because volunteer laboratories only represent themselves, they were automatically assigned a final weight of one.

NEAR estimation

The estimates in this publication are the weighted sum of the counts from each laboratory. The weighting procedures make the estimates more precise by assigning large weights to small laboratories and small weights to large laboratories.¹⁴ Because most of the values being estimated tend to be related to laboratory size, the product of the weight and the value to be estimated tend to be relatively stable across laboratories, resulting in precise estimates.

A finite population correction is also applied to account for the high sampling rate. In a sample-based design, the sampling fraction, which is used to create the weights, equals the number of sampled laboratories divided by the number of laboratories in the NFLIS universe. Under NEAR, the sampling fraction equals the number of sampled laboratories divided by the sum of the number of sampled laboratories and the number of nonreporting, unsampled laboratories. Volunteer laboratories are not included in the sampling fraction calculation. Thus, the NEAR approach makes the sampling rate even higher because volunteer laboratories do not count as nonsampled laboratories.

Suppression of Unreliable Estimates

For some drugs, such as cannabis/THC and cocaine, thousands of reports occur annually, allowing for reliable national prevalence estimates to be computed. For other drugs, reliable and precise estimates cannot be computed because of a combination of low report counts and substantial variability in report counts between laboratories. Thus, a suppression rule was established. Precision and reliability of estimates are evaluated using the relative standard error (RSE), which is the ratio between the standard error of an estimate and the estimate. Drug estimates with an RSE > 50% are suppressed and not shown in the tables.

¹⁴ See text reference footnote 12 in the right column of p. 25.

Statistical Techniques for Trend Analysis

Two types of analyses to compare estimates across years were used. The first is called *prior-year comparisons* and compared national and regional estimates from January 2012 through December 2012 with those from January 2013 through December 2013. The second is called *long-term trends* and examined trends in the annual national and regional estimates from January 2001 through December 2013. The long-term trends method described below was implemented beginning with the 2012 Midyear Report. The new method offers the ability to identify both linear and curved trends, unlike the method used in previous NFLIS publications. Both types of trend analyses are described below. For the region-level prior-year comparisons and long-term trends, the estimated drug reports were standardized to the most recent regional population totals for persons aged 15 years or older.

Prior-year comparisons

For selected drugs, the prior-year comparisons statistically compared estimates in Table 1.1 of this publication with estimates in Table 1.1 of the 2012 Annual Report. The specific test examined whether the difference between any two estimates was significantly different from zero. A standard *t*-test was completed using the statistic,

$$t_{df} = \frac{a\hat{T}_{2013} - b\hat{T}_{2012}}{\sqrt{a^2 \text{var}(\hat{T}_{2013}) + b^2 \text{var}(\hat{T}_{2012}) - 2ab \text{cov}(\hat{T}_{2012}, \hat{T}_{2013})}},$$

where

df = appropriate degrees of freedom (number of laboratories minus number of strata),

\hat{T}_{2013} = estimated total number of reports for the given drug for January 2013 through December 2013,

\hat{T}_{2012} = estimated total number of reports for the given drug for January 2012 through December 2012,

$\text{var}(\hat{T}_{2013})$ = variance of \hat{T}_{2013} ,

$\text{var}(\hat{T}_{2012})$ = variance of \hat{T}_{2012} , and

$\text{cov}(\hat{T}_{2012}, \hat{T}_{2013})$ = covariance between \hat{T}_{2012} and \hat{T}_{2013} .

For the national prior-year comparisons, $a = b = 1$. For the regional prior-year comparisons, $a = 100,000$ divided by the regional population total for 2013, and $b = 100,000$ divided by the regional population total for 2012.

The percentile of the test statistic in the *t* distribution determined whether the prior-year comparison was statistically significant (a two-tailed test at $\alpha = .05$).

Long-term trends

A long-term regression trends analysis was performed on the January 2001 through December 2013 annual national estimates of totals and regional estimates of rates for selected drug reports. The models allow for randomness in the totals and rates due to both the sample and the population. That is, for the vector of time period totals over that time,

$$\mathbf{Y}^T \equiv (Y_1, Y_2, \dots, Y_{13}),$$

and for the estimates,

$$\hat{\mathbf{Y}}^T \equiv (\hat{Y}_1, \hat{Y}_2, \dots, \hat{Y}_{13}),$$

the regression model is

$$\hat{\mathbf{Y}} = \mathbf{X}\beta + \eta + \varepsilon,$$

where

$\eta = \hat{\mathbf{Y}} - \mathbf{Y} = 13 \times 1$ vector of errors due to the probability sample, and

$\varepsilon = 13 \times 1$ vector of errors due to the underlying model.

Randomness due to the sample exists because only a sample of all eligible laboratories has been randomly selected to be included. Randomness due to the population exists because many factors that can be viewed as random contribute to the specific total reported by a laboratory in a time period. For example, not all drug seizures that could have been made were actually made, and there may have been some reporting errors. If rates (per 100,000 persons aged 15 years or older) and not totals are of interest, the above model can be applied to $\hat{\mathbf{Y}}^* = c\hat{\mathbf{Y}}$, where c equals 100,000 divided by the 15-or-older regional population size as given by the U.S. Census Bureau.

The regression model used to perform the analysis is

$$Y_t = \alpha_0 + \alpha_1 t + \alpha_2 t^2 + \alpha_3 t^3 + \varepsilon_t \quad t = 1, \dots, T,$$

where

Y_t = the population total value, considered to be a realization of the underlying model; and

ε_t = one of a set of 13 independent normal variates with a mean of zero and a variance of σ^2 .

The model allows for a variety of trend types: linear (straight-line), quadratic (U-shaped), and cubic (S-shaped). Because it is a model for Y_t but the sample estimates \hat{Y}_t differ by the sampling error, estimation was performed by restricted maximum likelihood (REML), allowing for the two sources of error.

To implement the regression model, point estimates of totals \hat{Y}_t and their standard errors were obtained for all 13 annual periods beginning with January to December 2001 period and ending with January to December 2013 period. Sampling standard errors were estimated as the full sampling variance-covariance matrix \mathbf{S} over these 13 time periods. The \mathbf{S} matrix contains variances in totals at any time period and covariances in totals between any two time periods, thus giving a very general modeling of the sampling variance structure. The variance-covariance matrix of the totals is then $V[\hat{\mathbf{Y}}] = \sigma^2 \mathbf{I} + \mathbf{S}$, where \mathbf{I} is the identity matrix.

Regression coefficients were estimated using the REML method. Because higher order polynomial regression models generally show strong collinearity among predictor variables, the model was reparameterized using orthogonal polynomials. The reparameterized model is

$$Y_t = \beta_0 X_0(t) + \beta_1 X_1(t) + \beta_2 X_2(t) + \beta_3 X_3(t) + \varepsilon_t,$$

where

$X_0(t) = 1/\sqrt{T}$ for all t , and

$X_1(t), X_2(t), X_3(t)$ provide contributions for the first-order (linear), second-order (quadratic), and third-order (cubic) polynomials, respectively.

Note that the error term is the same in both the original model and the reparameterized model because the fitted surface is the same for both models. The model was further constrained to have regression residuals sum to zero, a constraint that is not guaranteed by theory for these models, but was considered to improve model fit due to an approximation required to estimate \mathbf{S} . Standard errors of the regression trend estimates were obtained by simulation.

Final models were selected after testing for the significance of coefficients at the $\alpha = 0.05$ level ($p < .05$), which means that if the trend of interest (linear, quadratic, cubic) were in fact zero, then there would be a 5% chance that the trend would be detected as statistically significant when in fact it is not. Final fitted models are most easily interpreted using graphical plots.

State	Lab Type	Laboratory Name	Reporting
AK	State	Alaska Department of Public Safety	✓
AL	State	Alabama Department of Forensic Sciences (9 sites)	✓
AR	State	Arkansas State Crime Laboratory (2 sites)	✓
AZ	State	Arizona Department of Public Safety, Scientific Analysis Bureau (4 sites)	✓
	Local	Mesa Police Department	✓
	Local	Phoenix Police Department	✓
	Local	Scottsdale Police Department	✓
	Local	Tucson Police Department Crime Laboratory	✓
CA	State	California Department of Justice (10 sites)	✓
	Local	Alameda County Sheriff's Office Crime Laboratory (San Leandro)	✓
	Local	Contra Costa County Sheriff's Office (Martinez)	✓
	Local	Fresno County Sheriff's Forensic Laboratory	✓
	Local	Kern County District Attorney's Office (Bakersfield)	✓
	Local	Long Beach Police Department	✓
	Local	Los Angeles County Sheriff's Department (4 sites)	✓
	Local	Los Angeles Police Department (2 sites)	✓
	Local	Orange County Sheriff's Department (Santa Ana)	✓
	Local	Sacramento County District Attorney's Office	✓
	Local	San Bernardino Sheriff's Office (2 sites)	✓
	Local	San Diego County Sheriff's Department	✓
	Local	San Diego Police Department	✓
	Local	San Francisco Police Department*	✓
	Local	San Mateo County Sheriff's Office (San Mateo)	✓
	Local	Santa Clara District Attorney's Office (San Jose)	✓
	Local	Ventura County Sheriff's Department	✓
CO	State	Colorado Bureau of Investigation (5 sites)	✓
	Local	Aurora Police Department	✓
	Local	Colorado Springs Police Department	✓
	Local	Denver Police Department Crime Laboratory	✓
	Local	Jefferson County Sheriff's Office (Golden)	✓
CT	State	Connecticut Department of Public Safety	✓
DE	State	Chief Medical Examiner's Office	✓
FL	State	Florida Department of Law Enforcement (7 sites)	✓
	Local	Broward County Sheriff's Office (Fort Lauderdale)	✓
	Local	Indian River Crime Laboratory (Fort Pierce)	✓
	Local	Manatee County Sheriff's Office (Bradenton)	✓
	Local	Miami-Dade Police Department Crime Laboratory	✓
	Local	Palm Beach County Sheriff's Office Crime Laboratory (West Palm Beach)	✓
	Local	Pinellas County Forensic Laboratory (Largo)	✓
GA	State	Georgia State Bureau of Investigation (7 sites)	✓
	Local	Honolulu Police Department	✓
IA	State	Iowa Division of Criminal Investigations	✓
ID	State	Idaho State Police (3 sites)	✓
IL	State	Illinois State Police (7 sites)	✓
	Local	DuPage County Sheriff's Office (Wheaton)	✓
	Local	Northern Illinois Police Crime Laboratory (Chicago)	✓
IN	State	Indiana State Police Laboratory (4 sites)	✓
	Local	Indianapolis-Marion County Forensic Laboratory (Indianapolis)	✓
KS	State	Kansas Bureau of Investigation (4 sites)	✓
	Local	Johnson County Sheriff's Office (Mission)	✓
	Local	Sedgwick County Regional Forensic Science Center (Wichita)	✓
KY	State	Kentucky State Police (6 sites)	✓
LA	State	Louisiana State Police	✓
	Local	Acadiana Criminalistics Laboratory (New Iberia)	✓
	Local	Jefferson Parish Sheriff's Office (Metairie)	✓
	Local	New Orleans Police Department Crime Laboratory	✓
	Local	North Louisiana Criminalistics Laboratory System (3 sites)	✓
	Local	Southwest Louisiana Regional Laboratory (Lake Charles)	✓
MA	State	Massachusetts Department of Public Health (2 sites)	✓
	State	Massachusetts State Police	✓
	Local	University of Massachusetts Medical Center (Worcester)	✓
MD	State	Maryland State Police Forensic Sciences Division (3 sites)	✓
	Local	Anne Arundel County Police Department (Millersville)	✓
	Local	Baltimore City Police Department	✓
	Local	Baltimore County Police Department (Towson)	✓
	Local	Montgomery County Crime Laboratory (Rockville)	✓
	Local	Prince George's County Police Department (Landover)	✓
ME	State	Maine Department of Human Services	✓
MI	State	Michigan State Police (7 sites)*	✓
MN	State	Minnesota Bureau of Criminal Apprehension (2 sites)	✓
	Local	St. Paul Police Department	✓

This list identifies laboratories that are participating in and reporting to NFLIS as of July 1, 2014.

* This laboratory is not currently conducting drug chemistry analysis. Cases for the agencies they serve are being analyzed via contracts or agreements with other laboratories.

**The New York City Police Department Crime Laboratory currently reports summary data.

State	Lab Type	Laboratory Name	Reporting
MO	State	Missouri State Highway Patrol (8 sites)	✓
	Local	Independence Police Department	✓
	Local	KCMO Regional Crime Laboratory (Kansas City)	✓
	Local	St. Charles County Criminalistics Laboratory (O'Fallon)	✓
	Local	St. Louis County Crime Laboratory (Clayton)	✓
MS	State	Mississippi Department of Public Safety (4 sites)	✓
	Local	Jackson Police Department Crime Laboratory	✓
	Local	Tupelo Police Department	✓
MT	State	Montana Forensic Science Division	✓
NC	State	North Carolina State Bureau of Investigation (3 sites)	✓
	Local	Charlotte-Mecklenburg Police Department	✓
ND	State	North Dakota Crime Laboratory Division	✓
NE	State	Nebraska State Patrol Criminalistics Laboratory (2 sites)	✓
NH	State	New Hampshire State Police Forensic Laboratory	✓
NJ	State	New Jersey State Police (4 sites)	✓
	Local	Burlington County Forensic Laboratory (Mt. Holly)	✓
	Local	Cape May County Prosecutor's Office	✓
	Local	Hudson County Prosecutor's Office (Jersey City)	✓
	Local	Ocean County Sheriff's Department (Toms River)	✓
	Local	Union County Prosecutor's Office (Westfield)	✓
NM	State	New Mexico Department of Public Safety (3 sites)	✓
	Local	Albuquerque Police Department	✓
NV	Local	Las Vegas Metropolitan Police Crime Laboratory	✓
	Local	Washoe County Sheriff's Office Crime Laboratory (Reno)	✓
NY	State	New York State Police (4 sites)	✓
	Local	Erie County Central Police Services Laboratory (Buffalo)	✓
	Local	Nassau County Office of Medical Examiner (East Meadow)	✓
	Local	New York City Police Department Crime Laboratory**	✓
	Local	Niagara County Police Department (Lockport)	✓
	Local	Onondaga County Center for Forensic Sciences (Syracuse)	✓
	Local	Suffolk County Crime Laboratory (Hauppauge)	✓
	Local	Westchester County Forensic Sciences Laboratory (Valhalla)	✓
	Local	Yonkers Police Department Forensic Science Laboratory	✓
OH	State	Ohio Bureau of Criminal Identification & Investigation (3 sites)	✓
	State	Ohio State Highway Patrol	✓
	Local	Canton-Stark County Crime Laboratory (Canton)	✓
	Local	Columbus Police Department	✓
	Local	Cuyahoga County Regional Forensic Science Laboratory (Cleveland)	✓
	Local	Hamilton County Coroner's Office (Cincinnati)	✓
	Local	Lake County Regional Forensic Laboratory (Painesville)	✓
	Local	Mansfield Police Department	✓
	Local	Miami Valley Regional Crime Laboratory (Dayton)	✓
	Local	Newark Police Department Forensic Services	✓
OK	State	Oklahoma State Bureau of Investigation (5 sites)	✓
	Local	Tulsa Police Department Forensic Laboratory	✓
OR	State	Oregon State Police Forensic Services Division (5 sites)	✓
PA	State	Pennsylvania State Police Crime Laboratory (6 sites)	✓
	Local	Allegheny County Coroner's Office (Pittsburgh)	✓
	Local	Bucks County Crime Laboratory (Warminster)	✓
	Local	Philadelphia Police Department Forensic Science Laboratory	✓
RI	State	Rhode Island Forensic Sciences Laboratory	✓
SC	State	South Carolina Law Enforcement Division	✓
	Local	Anderson/Oconee Regional Forensics Laboratory	✓
	Local	Charleston Police Department	✓
	Local	Richland County Sheriff's Department Forensic Sciences Laboratory (Columbia)	✓
	Local	Spartanburg Police Department	✓
SD	State	South Dakota Department of Public Health Laboratory	✓
	Local	Rapid City Police Department	✓
TN	State	Tennessee Bureau of Investigation (3 sites)	✓
TX	State	Texas Department of Public Safety (13 sites)	✓
	Local	Austin Police Department	✓
	Local	Bexar County Criminal Investigations Laboratory (San Antonio)	✓
	Local	Brazoria County Crime Laboratory (Angleton)	✓
	Local	Fort Worth Police Department Criminalistics Laboratory	✓
	Local	Harris County Medical Examiner's Office (Houston)	✓
	Local	Jefferson County Sheriff's Regional Crime Laboratory (Beaumont)	✓
	Local	Pasadena Police Department	✓
UT	State	Utah State Crime Laboratory (3 sites)	✓
VA	State	Virginia Department of Forensic Science (4 sites)	✓
VT	State	Vermont Forensic Laboratory	✓
WA	State	Washington State Patrol (6 sites)	✓
WI	State	Wisconsin Department of Justice (3 sites)	✓
WV	State	West Virginia State Police	✓
WY	State	Wyoming State Crime Laboratory	✓
PR	Territory	Puerto Rico Crime Laboratory (3 sites)	✓

Benefits

The systematic collection and analysis of drug analysis data aid our understanding of the Nation's illicit drug problem. NFLIS serves as a resource for supporting drug scheduling policy and drug enforcement initiatives both nationally and in specific communities around the country.

Specifically, NFLIS helps the drug control community achieve its mission by

- providing detailed information on the prevalence and types of controlled substances secured in law enforcement operations;
- identifying variations in controlled and noncontrolled substances at the national, State, and local levels;
- identifying emerging drug problems and changes in drug availability in a timely fashion;
- monitoring the diversion of legitimately marketed drugs into illicit channels;
- providing information on the characteristics of drugs, including quantity, purity, and drug combinations; and
- supplementing information from other drug sources, including the DEA's STRIDE, the National Survey on Drug Use and Health (NSDUH), and the Monitoring the Future (MTF) study.

NFLIS is an opportunity for State and local laboratories to participate in a useful, high-visibility initiative. Participating laboratories regularly receive reports that summarize national and regional data. In addition, the Data Query System (DQS) is a secure website that allows NFLIS participants—including State and local laboratories, the DEA, and other Federal drug control agencies—to run customized queries on the NFLIS data. Enhancements to the DQS provide a new interagency exchange forum that will allow the DEA, forensic laboratories, and other members of the drug control community to post and respond to current information.

Limitations

NFLIS has limitations that must be considered when interpreting findings generated from the database.

- Currently, NFLIS includes data from Federal, State, and local forensic laboratories. Federal data are shown separately in this publication. Efforts are under way to enroll additional Federal laboratories.
- NFLIS includes drug chemistry results from completed analyses only. Drug evidence secured by law enforcement but not analyzed by laboratories is not included in the database.
- National and regional estimates may be subject to variation associated with sample estimates, including nonresponse bias.
- State and local policies related to the enforcement and prosecution of specific drugs may affect drug evidence submissions to laboratories for analysis.
- Laboratory policies and procedures for handling drug evidence vary. Some laboratories analyze all evidence submitted to them, while others analyze only selected case items. Many laboratories do not analyze drug evidence if the criminal case was dismissed from court or if no defendant could be linked to the case.
- Laboratories vary with respect to the records they maintain. For example, some laboratories' automated records include the weight of the sample selected for analysis (e.g., the weight of one of five bags of powder), while others record total weight.

The NFLIS website (<https://www.nflis.deadiversion.usdoj.gov/>) is an important feature of the NFLIS program. It is the key resource to provide NFLIS-related information, both through a public site and through a private site, which gives secure access to the NFLIS DQS.

The public site is frequently updated with NFLIS-related news, including information relevant to drug control efforts and DEA participation in conferences. Also available are downloadable versions of published NFLIS reports, links to other websites, and contact information to key NFLIS staff. Public features include links to mass spectral libraries, such as the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) library at <http://www.swgdrug.org/> and the ForensicDB library at <https://www.forensicdb.org/>.

The private site requires user accounts, and security roles are assigned to manage access to its features, including the Map Library, NFLIS Data Entry Application, and DQS. The DQS is a distinct resource for NFLIS reporting laboratories to run customizable queries on their own case-level data and on aggregated metropolitan, State, regional, and national data. Features include the drug category queries for synthetic cannabinoids and synthetic cathinones.

To obtain information about NFLIS participation or the DQS, please visit the NFLIS website at <https://www.nflis.deadiversion.usdoj.gov/>.

The screenshot displays the NFLIS website interface. At the top, the header includes the Drug Enforcement Administration (DEA) logo, the text "Drug Enforcement Administration Office Of Diversion Control", the "NFLIS" logo, and the text "National Forensic Laboratory Information System". A navigation bar contains links: NFLIS Home, DQS, Drug Information System Use Agreement, Drug Information System, My Options, Participation, Data Elements, Reports, Related Links, Contacts, FAQ, Site Map, and Admin. A search bar is located on the right. Below the navigation bar, the main content area is titled "NFLIS Drug Information System" and features a forum section. The forum section has a table with columns: Forums, Threads, Posts, and Last Post. The table lists several discussion topics, including "Drug Identification Issues", "Drug Standards", "Synthetic Cannabinoids", "Arylcyclohexamines", "Tryptamines", "Phenylalkylamines", and "Piperazines". Each row shows the number of threads and posts, and the last post date and time.

Forums	Threads	Posts	Last Post
Discussions > Drug Talk			
Drug Identification Issues	1	3	None
Drug Standards	0	0	None
Synthetic Cannabinoids This is a discussion group for synthetic cannabinoids.	1	1	Synthetic Canna... 4/22/2013 10:34 AM by RTI_0001
Arylcyclohexamines Discussions relevant to Arylcyclohexamines	1	1	Arylcyclohexami... 11/6/2013 11:29 AM by RTI_0001
Tryptamines Discussions related to Tryptamines	1	1	Tryptamines Che... 11/6/2013 9:33 PM by RTI_0001
Phenylalkylamines Discussions related to Phenylalkylamines	1	1	Phenylalkylami... 11/6/2013 11:43 AM by RTI_0001
Piperazines Discussions related to Piperazines	1	1	Piperazines Che... 11/6/2013 9:34 PM by RTI_0001

PUBLIC DOMAIN NOTICE

All material appearing in this publication is in the public domain and may be reproduced or copied without permission from the DEA. However, this publication may *not* be reproduced or distributed for a fee without the specific, written authorization of the U.S. Drug Enforcement Administration, U.S. Department of Justice. Citation of the source is appreciated. Suggested citation:

U.S. Drug Enforcement Administration, Office of Diversion Control. (2014). *National Forensic Laboratory Information System: Year 2013 Annual Report*. Springfield, VA: U.S. Drug Enforcement Administration.

OBTAINING COPIES OF THIS PUBLICATION

Electronic copies of this publication can be downloaded from the NFLIS website at <https://www.nflis.deadiversion.usdoj.gov>.



U.S. Drug Enforcement Administration
Office of Diversion Control
8701 Morrisette Drive
Springfield, VA 22152

August 2014